561 results match your criteria Small Cell Carcinoma of the Prostate


Effective treatment of relapsed prostate small cell carcinoma with amrubicin: report of a case.

Int Cancer Conf J 2020 Jul 13;9(3):155-158. Epub 2020 May 13.

Department of Urology, Japan Organization of Occupational Health and Safety, Chugoku Rosai Hospital, 1-5-1 Hirotagaya, Kure, 737-0193 Japan.

Standard therapy for metastatic small cell carcinoma of the prostate (SCCP) remains undefined. We have effectively treated relapsed SCCP with amrubicin. A 72-year-old patient, diagnosed with T4N1M0 prostate cancer, started hormonal therapy in May 2012, elsewhere, and his prostate-specific antigen levels remained low. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13691-020-00416-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297924PMC

Not such a small diagnosis: small cell carcinoma of the prostate.

J Surg Case Rep 2020 Jun 17;2020(6):rjaa117. Epub 2020 Jun 17.

Department of Pathology, Leighton Hospital, Middlewich Road, Crewe, UK.

Small cell carcinoma (SCC) is an aggressive malignancy most commonly described in the lung. We present a case of a 61-year-old male who presented with a neck swelling and was subsequently found to have metastatic SCC of the prostate. Clinicians should be aware that it metastasizes early. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jscr/rjaa117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299610PMC

A rare case of penile metastases from small cell prostate cancer.

Rev Int Androl 2020 Jun 20. Epub 2020 Jun 20.

Urology Department, Hospital Universitario Sanitas La Moraleja, Universidad Francisco de Vitoria, Madrid, Spain.

We present a case of an 83-year-old-male with painless penile nodules several months after he was diagnosed with pure prostatic small cell carcinoma. Penile doppler ultrasound and magnetic resonance imaging demonstrated solid nodules in both corpora cavernosa. Fine-needle aspiration of the nodules with immunohistochemical examination confirmed prostatic small cell carcinoma origin of metastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.androl.2019.11.003DOI Listing

Misdiagnosis of Small Cell Prostate Cancer: Lessons Learned.

Cureus 2020 May 29;12(5):e8356. Epub 2020 May 29.

Genitourinary Oncology, Creighton University School of Medicine/University of Arizona Cancer Center at Dignity Health, Phoenix, USA.

Small cell carcinoma (SCC) of the prostate is rare in the spectrum of prostate tumors. Clinically, prostate SCC is more aggressive and has a poorer prognosis when compared to prostate acinar adenocarcinoma. Delay in diagnosis and misdiagnosis further worsens the outcome of this disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.8356DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263708PMC

[The Efficacy of Amrubicin Therapy as a Second Line Treatment in Patients with Small Cell Carcinoma of the Prostate : A Case Report].

Hinyokika Kiyo 2020 Apr;66(4):121-125

The Department of Urology, Gifu University Graduate School of Medicine.

A 68-year-old man was diagnosed with prostate cancer (initial serum prostate specific antigen [PSA] 389 ng/ml, stage cT4N1M1c, Gleason score 5+4), and androgen deprivation therapy was initiated. Despite the low serum PSA level, he developed postrenal acute kidney failure 4 years later, with progression of prostate cancer and liver and lung metastases. Serum levels of neuron-specific enolase and pro-gastrinreleasing peptide (tumor markers) were elevated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14989/ActaUrolJap_66_4_121DOI Listing

Evaluation of Somatostatin and CXCR4 Receptor Expression in a Large Set of Prostate Cancer Samples Using Tissue Microarrays and Well-Characterized Monoclonal Antibodies.

Transl Oncol 2020 Sep 24;13(9):100801. Epub 2020 May 24.

Institute of Pharmacology and Toxicology, Jena University Hospital, Jena, Germany. Electronic address:

Background: Prostate cancer (PCa) is the most common type of cancer among men in Western countries. Despite numerous therapeutic options, few treatments are available for patients with end-stage disease. In the present study, different somatostatin receptors (SSTs) and the chemokine receptor CXCR4 were evaluated for their suitability as novel therapeutic targets in PCa. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tranon.2020.100801DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249232PMC
September 2020

Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate.

Hum Pathol 2020 Jul 7;101:70-79. Epub 2020 May 7.

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, 21287, USA.

Small-cell neuroendocrine carcinoma (SCNC) of the prostate is an aggressive subtype with frequent TP53 mutation and RB1 inactivation; however, the molecular phenotype remains an area of investigation. Here, we compared telomere lengths in prostatic SCNC and usual-type prostatic adenocarcinoma (AdCa). We studied 32 cases of prostatic SCNC (including 11 cases with concurrent AdCa) and 347 cases of usual-type AdCa on tissue microarrays. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2020.04.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321874PMC

Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer.

Cells 2020 Apr 25;9(5). Epub 2020 Apr 25.

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

The term aggressive variant prostate cancer (AVPCa) refers to androgen receptor (AR)-independent anaplastic forms of prostate cancer (PCa), clinically characterized by a rapidly progressive disease course. This involves hormone refractoriness and metastasis in visceral sites. Morphologically, AVPCa is made up of solid sheets of cells devoid of pleomorphism, with round and enlarged nuclei with prominent nucleoli and slightly basophilic cytoplasm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells9051073DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291250PMC

Small Cell Carcinoma of the Prostate: A Case Report and Review of the Literature.

Cureus 2020 Feb 22;12(2):e7074. Epub 2020 Feb 22.

Pathology, G.V. (Sonny) Montgomery VA Medical Center, Jackson, USA.

Small cell carcinoma of the prostate (SCCP) is a rare malignancy that is considered a lethal entity of prostate cancer. Once it is diagnosed, patients characteristically experience an aggressive clinical course with poor overall survival rates, which unfortunately still holds even with modern treatments. In this report, we discuss the case of a 63-year-old African American male who initially presented to the hospital with an elevated prostate-specific antigen (PSA) level of 9. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7074DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093915PMC
February 2020

[Small-cell carcinoma of the prostate: A report of 2 cases and review of the literature].

Zhonghua Nan Ke Xue 2019 Feb;25(2):150-153

Department of Urology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, China.

Objective: To investigate the clinicopathological characteristics and improve the clinical treatment of prostatic small-cell carcinoma (PSCC).

Methods: We reported 2 cases of PSCC derived from prostate cancer after treated by androgen blockade and prostate electrotomy and reviewed the relevant literature.

Results: Two patients with PSA elevation were diagnosed with prostate cancer by prostatic puncture biopsy and treated by maximum androgen blockade, which reduced their total PSA to the normal level. Read More

View Article

Download full-text PDF

Source
February 2019

Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis.

PLoS One 2020 13;15(3):e0230272. Epub 2020 Mar 13.

Small Animal Clinic, University of Veterinary Medicine Hannover, Hannover, Germany.

Canine prostate adenocarcinoma (PAC) and transitional cell carcinoma (TCC) of prostate and urinary bladder are highly invasive and metastatic tumors of closely neighbored organs. Cell lines are valuable tools to investigate tumor mechanisms and therapeutic approaches in vitro. PAC in dogs is infrequent, difficult to differentiate from TCC and usually characterized by poor prognosis, enhancing the value of the few available cell lines. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0230272PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069630PMC

ECTOPIC ADRENOCORTICOTROPIC HORMONE SYNDROME DUE TO METASTATIC PROSTATE CANCER WITH NEUROENDOCRINE DIFFERENTIATION.

AACE Clin Case Rep 2019 May-Jun;5(3):e192-e196. Epub 2019 Apr 25.

Objective: Neuroendocrine differentiation of prostate cancer can result in ectopic adrenocorticotropic hormone (ACTH) secretion (EAS) and Cushing syndrome. The aim of this report is to highlight this unusual mechanism of hypercortisolism and its management.

Methods: We report a 73-year-old patient with a history of prostate adenocarcinoma who presented with severe weakness, hyperglycemia, and hypokalemia caused by EAS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4158/ACCR-2018-0429DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876939PMC

Incidental Lymphoplasmacytic Lymphoma Diagnosed Following Robotic-Assisted Laparoscopic Prostatectomy for Prostate Cancer.

Curr Urol 2019 Nov 13;13(3):166-168. Epub 2019 Nov 13.

Department of Urology, Lister Hospital, Stevenage.

We report a case of prostatic lymphoma of the Walden-ström's macroglobulinemia subtype in a 64-year-old gentleman who underwent a robotic-assisted laparoscopic prostatectomy following lower urinary tract symptoms and high grade adenocarcinoma on transperineal prostate biopsy's. Histopathological and immunohistochemistry analysis at the time of surgery was consistent with a CD5-negative small B-cell lymphoma. To our knowledge this is the first reported prostatic lymphoma identified following robotic-assisted laparoscopic prostatectomy and the first documented case of lymphoplasmacytic lymphoma involving prostate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499275DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944894PMC
November 2019

Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN in combination with chemotherapy.

Future Sci OA 2019 Oct 29;5(10):FSO435. Epub 2019 Oct 29.

R&D, APAC Biotech Pvt Ltd, Gurgaon, India.

Of the most prevalent solid tumors with advanced disease, prostate and ovarian cancer and non-small cell lung carcinoma have the fewest therapeutic options. Herein, we report the case of a 63-year-old male with metastatic prostate adenocarcinoma showing substantial remission post-administration of personalized dendritic cell-based vaccine APCEDEN in combination with chemotherapeutic drug Mitoxantrone. Therapeutic response displayed an interesting clinical correlation validated by PET scan images showing decreased fluorodeoxyglucose (FDG) avidity in the prostate gland, reduced skeletal metastases further established by the drop in serum Prostate Specific Antigen (PSA) levels and expression of immune assessment markers (IFN-γ, Tregs, neutrophil lymphocyte ratio and platelet lymphocyte ratio). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2144/fsoa-2019-0086DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900976PMC
October 2019

False-Negative Histopathologic Diagnosis of Prostatic Adenocarcinoma.

Arch Pathol Lab Med 2020 Mar 15;144(3):326-334. Epub 2019 Nov 15.

From the Department of Pathology, Yale School of Medicine, New Haven, Connecticut.

Context.—: Histopathologic diagnosis of adenocarcinoma of the prostate is based on light-microscopic examination of hematoxylin-eosin-stained tissue sections. Multiple factors, including preanalytic and analytic elements, affect the ability of the pathologist to accurately diagnose prostatic adenocarcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2019-0456-RADOI Listing
March 2020
2.838 Impact Factor

Novel genetic variants in HDAC2 and PPARGC1A of the CREB-binding protein pathway predict survival of non-small-cell lung cancer.

Mol Carcinog 2020 01 12;59(1):104-115. Epub 2019 Nov 12.

Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina.

The CREB-binding protein (CBP) pathway plays an important role in transcription and activity of acetyltransferase that acetylates lysine residues of histones and nonhistone proteins. In the present study, we hypothesized that genetic variants in the CBP pathway genes played a role in survival of non-small-cell lung cancer (NSCLC). We tested this hypothesis using the genotyping data from the genome-wide association study (GWAS) dataset from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mc.23132DOI Listing
January 2020
4.808 Impact Factor

Primary yolk sac tumour of the prostate mimicking small round blue cell tumour.

Curr Oncol 2019 10 1;26(5):e707. Epub 2019 Oct 1.

Department of Pathology and Laboratory Medicine, Pennsylvania Hospital of the University of Pennsylvania Health System, Philadelphia, PA, U.S.A.

Prostatic yolk sac tumour is a germ cell tumour with a wide range of age of occurrence, unusual anatomic locations, diverse morphologic patterns, and aggressive biologic behavior, posing challenges both to diagnosis and clinical management. We report a rare case of primary yolk sac tumour of the prostate with extensive local and liver metastasis, the latter of which exhibited sheets of small blue cells expressing CD99 and focal sall4 on biopsy. Positivity for CD99 and gata3 in the initial biopsy raised the differential diagnosis of Ewing sarcoma and poorly differentiated carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.5179DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821123PMC
October 2019

Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.

J Nucl Med 2020 Jan 20;61(1):70-79. Epub 2019 Sep 20.

Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany

Prostate-specific membrane antigen (PSMA)-binding tracers have been shown to be promising agents for the specific targeting of prostate tumors. On labeling with the short-lived isotopes F and Ga, excellent molecular imaging performance is achieved. This potential could be further exploited using long-lived isotopes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.119.229054DOI Listing
January 2020
3 Reads
6.160 Impact Factor

Knockdown of COPS3 inhibits the progress of prostate cancer through reducing phosphorylated p38 MAPK expression and impairs the epithelial-mesenchymal transition process.

Prostate 2019 12 11;79(16):1823-1831. Epub 2019 Sep 11.

Urology and Lithotripsy Center, Peking University People's Hospital, Beijing, China.

Background: The amplification of gene COPS3 is closely related to the development of osteosarcoma and hepatocellular carcinoma. However, the effects of COPS3 on prostate cancer (PCa) are poorly understood.

Methods: In this study, the protein expression of COPS3 in PCa tissues, adjacent normal tissues, and bone metastasis tissues of PCa was analyzed by immunohistochemistry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23907DOI Listing
December 2019
4 Reads

New-Onset Resistant Hypertension in a Newly Diagnosed Prostate Cancer Patient.

Am J Hypertens 2019 11;32(12):1214-1217

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.

Background: New onset resistant hypertension in a previously stable patient with chronic hypertension should lead to consideration of secondary causes. Electrolyte abnormalities are useful clues for identifying some common causes, especially mineralocorticoid excess.

Case Presentation: We report the case of a 69-year-old man who developed severe resistant hypertension despite the use of 6 antihypertensive medications, including diuretics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajh/hpz125DOI Listing
November 2019
4 Reads

Impact of Timeliness of Surgical Treatment on the Outcomes of Patients with Non-metastatic Non-small Cell Lung Cancer: Findings From the PLCO Trial.

World J Surg 2019 11;43(11):2927-2933

Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, T6G 1Z2, Canada.

Background: This study aimed to assess the impact of timeliness of surgical resection among patients with non-metastatic non-small cell lung cancer (NSCLC) treated with upfront surgery.

Methods: Cases with confirmed non-metastatic NSCLC diagnosis treated with upfront surgery within the cohort of participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial were included in the current study. Multivariate logistic regression analysis was used to assess factors predicting time from diagnosis to surgical resection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00268-019-05089-6DOI Listing
November 2019
2 Reads
2.642 Impact Factor

Patterns of care and outcomes in small cell carcinoma of the prostate: A national cancer database analysis.

Prostate 2019 09 11;79(12):1457-1461. Epub 2019 Jul 11.

Division of Radiation Oncology, Allegheny Health Network, Pittsburgh, Pennsylvania.

Background: Small cell carcinoma (SCC) of the prostate is a rare, aggressive disease. Evidence is limited; however, the current standard of care is chemotherapy. The benefit of local treatment modalities is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23864DOI Listing
September 2019
2 Reads

Modelling the internalisation process of prostate cancer cells for PSMA-specific ligands.

Nucl Med Biol 2019 May - Jun;72-73:20-25. Epub 2019 May 29.

Department of Nuclear Medicine, Ulm University, Ulm, Germany; Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, Germany. Electronic address:

Introduction: In prostate-specific membrane antigen (PSMA)-targeting radioligand therapy, small molecules are regularly internalised by the tumour cells. To determine the effectiveness of these ligands, the internalised fraction over time is derived from cell studies. Parameters, such as the ligand concentration and the number of cells, are experiment-specific and therefore a comparison between ligands is difficult. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09698051193002
Publisher Site
http://dx.doi.org/10.1016/j.nucmedbio.2019.05.003DOI Listing
May 2020
6 Reads

Multiple osteolytic bone and lung metastases from prostate cancer including small cell carcinoma with marked increases in CEA and Pro-GRP.

Urol Case Rep 2019 May 26;24:100883. Epub 2019 Mar 26.

General Medicine, Musashino Red Cross Hospital, Tokyo, Japan.

It is known that prostate cancer usually presents as adenocarcinoma, frequently metastasizes to bone, appears osteoblastic on radiographs, and shows elevated PSA. Herein, we describe a case of an 80-year-old man diagnosed with prostate cancer presenting as adenocarcinoma and small cell carcinoma in different areas as well as osteolytic bone metastases in the ilium, right rib, vertebrae, and bilateral femurs with markedly elevated CEA (2391 ng/mL) and Pro-GRP (2610 pg/mL). Occasionally, prostate cancer can appear as osteolytic bone metastases, and in this case, it is possible that the prostate cancer contained small cell carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eucr.2019.100883DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562363PMC
May 2019
5 Reads

Utility of NKX3.1 Immunostaining in the Detection of Metastatic Prostatic Carcinoma on Fine-Needle Aspiration Smears.

Am J Clin Pathol 2019 09;152(4):495-501

Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston.

Objectives: NK3 homeobox 1 (NKX3.1) has been increasingly used to diagnose metastatic prostatic carcinoma in histologic samples. However, its utility and reliability in cytologic direct smears have not been studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajcp/aqz063DOI Listing
September 2019
7 Reads

Potentially functional genetic variants in the TNF/TNFR signaling pathway genes predict survival of patients with non-small cell lung cancer in the PLCO cancer screening trial.

Mol Carcinog 2019 07 15;58(7):1094-1104. Epub 2019 Apr 15.

Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina.

The tumor necrosis factor (TNF)/TNF receptor (TNFR) pathway is known to influence survival of patients with cancer. We hypothesize that single nucleotide polymorphisms (SNPs) in the TNF/TNFR pathway genes related to apoptosis are associated with survival of patients with non-small cell lung cancer (NSCLC). We used 1185 patients with NSCLC in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial and 984 patients with NSCLC in the Harvard Lung Cancer Susceptibility Study as the discovery and validation datasets, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mc.23017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548610PMC
July 2019
5 Reads
4.808 Impact Factor

Magnetic resonance imaging-guided transperineal prostate biopsy.

J Cancer Res Ther 2019 ;15(2):394-397

Department of Intervention, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.

Purpose: The purpose of the study is to assess the clinical value of magnetic resonance imaging (MRI)-guided transperineal prostate biopsy in the diagnosis of prostate disease.

Materials And Methods: The institutional ethics committee approved this study. MRI-guided transperineal prostate biopsy was performed on 78 patients who had presented to our hospital with a prostate-specific antigen level >4 ng/mL or with MRI scans suggesting prostate cancer between January 2015 and August 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcrt.JCRT_725_18DOI Listing
July 2019
5 Reads

Microarray-based data mining reveals key genes and potential therapeutic drugs for Cadmium-induced prostate cell malignant transformation.

Environ Toxicol Pharmacol 2019 May 15;68:141-147. Epub 2019 Mar 15.

Institute of Cancer, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, China. Electronic address:

Increasing evidence showed that Cadmium (Cd) can accumulate in the body and damage cells, resulting in cancerigenesis of the prostate with complex mechanisms. In the present study, we aimed to explore the possible key genes, pathways and therapeutic drugs using bioinformatics methods. Microarray-based data were retrieved and analyzed to screen differentially expressed genes (DEGs) between Cd-treated prostate cells and controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.etap.2019.03.014DOI Listing
May 2019
6 Reads

Incidentally Detected Oropharyngeal Squamous Cell Carcinoma on 18F-Fluciclovine PET/CT.

Clin Nucl Med 2019 May;44(5):e367-e369

From the Division of Nuclear Medicine, Department of Radiology and Biomedical Imaging.

We present a case of oropharyngeal squamous cell carcinoma (SCC) of the tongue base incidentally detected on F-fluciclovine PET/CT. A 79-year-old man with history of locally advanced prostate cancer (Gleason score 4 + 5 = 9; cT2cN1M0) previously treated with androgen deprivation therapy (luprolide + bicalutamide) presented with a slowly rising serum prostate-specific antigen over 3 years, concerning for recurrent disease. F-fluciclovine PET/CT, obtained to identify potential sites of recurrence, demonstrated prostate bed uptake with possible left seminal vesicle involvement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002507DOI Listing
May 2019
34 Reads

Urothelial carcinoma with villoglandular differentiation (UCVGD) with small cell neuroendocrine carcinoma of urinary bladder.

BMJ Case Rep 2019 Jan 18;12(1). Epub 2019 Jan 18.

Urology, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, Orissa, India.

Urothelial carcinoma with villoglandular differentiation (UCVGD) is a rare aggressive variant of urothelial carcinoma. It is usually associated with high-grade urothelial carcinoma or rarely adenocarcinoma. There is only one other previous report of UCVGD associated with small cell neuroendocrine carcinoma of urinary bladder. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-228017DOI Listing
January 2019
13 Reads

Poorly Differentiated Small-Cell-Type Neuroendocrine Carcinoma of the Prostate: A Case Report and Literature Review.

Case Rep Oncol 2018 Sep-Dec;11(3):676-681. Epub 2018 Oct 31.

Department of Medicine, Bronx Lebanon Hospital Center, Bronx, New York, USA.

Neuroendocrine cells are widespread throughout the body and can give rise of neuroendocrine tumors due to abnormal growth of the chromaffin cells. Neuroendocrine tumors divide into many subtypes based on tumor grade (Ki-67 index and mitotic count) and differentiation. These tumors can be further divided into secretory and nonsecretory types based on the production of peptide hormone by tumor cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000493255DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243899PMC
October 2018
7 Reads

Asynchronous tumour quadruplicity: rectosigmoid adenocarcinoma, renal cell carcinoma, prostate adenocarcinoma and neuroendocrine small-cell lung cancer - a case report.

Rozhl Chir Summer 2018;97(9):427-431

Introduction: Multiple tumors belong to rare cancers. Almost all malignancies may occur in combination, the most common combination being gastrointestinal cancer with respiratory or urogenital tract cancer and with breast cancer in females.

Case Report: In 1999, a 66-year-old patient was diagnosed with a rectosigmoid tumor histologically proven as adenocarcinoma. Read More

View Article

Download full-text PDF

Source
April 2019
31 Reads

Lesson of the month 2: An unusual cause of depression in an older man: Cushing's syndrome resulting from metastatic small cell cancer of the prostate.

Clin Med (Lond) 2018 10;18(5):432-434

Royal Adelaide Hospital, Adelaide, Australia.

This article describes the case of an older patient whose main presenting problem was depression. A constellation of clinical and biochemical features led to a search for medical causes of his low mood, which uncovered ectopic adrenocorticotropic hormone (ACTH) secretion. Post-mortem examination showed that the source of ACTH was small cell neuroendocrine carcinoma of the prostate, and that the patient had died from the sequelae of profound immune suppression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7861/clinmedicine.18-5-432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334104PMC
October 2018
8 Reads

Small Cell Transformation of Metastatic Prostate Adenocarcinoma Diagnosed by Dual-Tracer PET/CT (Ga-PSMA and F-FDG): Potential Clinical Utility in Therapeutic Decision Making and Treatment Monitoring.

J Nucl Med Technol 2019 Mar 23;47(1):85-87. Epub 2018 Aug 23.

Radiation Medicine Centre, Tata Memorial Hospital Annexe, Mumbai, India; and Homi Bhabha National Institute, Mumbai, India

Transformed small cell carcinoma of the prostate represents a tumor biology distinct from its adenocarcinoma counterpart, and penile metastasis from prostate cancer is a rare phenomenon. Biologic heterogeneity among metastatic lesions in a patient with prostatic adenocarcinoma with SCPCa transformation is presented here. The case report shows the significance of using dual-tracer PET/CT with Ga-prostate-specific membrane antigen and F-FDG in diagnosing small cell carcinoma of prostate transformation in certain lesions, thereby guiding therapeutic strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnmt.118.215582DOI Listing
March 2019
17 Reads

DUSP1 is involved in the progression of small cell carcinoma of the prostate.

Saudi J Biol Sci 2018 Jul 18;25(5):858-862. Epub 2017 Oct 18.

The First Hospital of Shijiazhuang, Shijiangzhuang 050011, PR China.

Small cell carcinoma of the prostate (SCCP) is a rare and the most aggressive variant of prostate cancer. There is no effective cure or treatment for SCCP. Therefore, there is an urgent need for new therapy to improve the prognosis of patients with SCCP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sjbs.2017.09.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088105PMC
July 2018
30 Reads
0.741 Impact Factor

Pure small-cell carcinoma of the prostate presenting with increasing prostate-specific antigen levels: A case report and review of the literature.

Mol Clin Oncol 2018 Aug 4;9(2):197-200. Epub 2018 Jun 4.

Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China.

The incidence of prostatic cancer (PCa) has increased significantly, and the measurement of prostate-specific antigen (PSA) is an effective screening tool for its diagnosis. PCa includes a number of specific clinicopathological types, including squamous cell, urothelial, adenoid cystic and small-cell carcinoma, among which small-cell carcinoma of the prostate (SCCP) is extremely rare, accounting for <0.5% of all PCa cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mco.2018.1644DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6083420PMC
August 2018
22 Reads

Regulation of monoamine oxidase A (MAO-A) expression, activity, and function in IL-13-stimulated monocytes and A549 lung carcinoma cells.

J Biol Chem 2018 09 18;293(36):14040-14064. Epub 2018 Jul 18.

From the Department of Biotechnology, National Institute of Technology-Durgapur, Mahatma Gandhi Avenue, Durgapur-713209, Burdwan, West Bengal, India,

Monoamine oxidase A (MAO-A) is a mitochondrial flavoenzyme implicated in the pathogenesis of atherosclerosis and inflammation and also in many neurological disorders. MAO-A also has been reported as a potential therapeutic target in prostate cancer. However, the regulatory mechanisms controlling cytokine-induced MAO-A expression in immune or cancer cells remain to be identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.RA118.002321DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130935PMC
September 2018
11 Reads

Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer.

Int J Cancer 2018 11 21;143(10):2400-2408. Epub 2018 Sep 21.

Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, 27710.

The toll-like receptor (TLR) signaling pathway plays an important role in the innate immune responses and antigen-specific acquired immunity. Aberrant activation of the TLR pathway has a significant impact on carcinogenesis or tumor progression. Therefore, we hypothesize that genetic variants in the TLR signaling pathway genes are associated with overall survival (OS) of patients with non-small cell lung cancer (NSCLC). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ijc.31660
Publisher Site
http://dx.doi.org/10.1002/ijc.31660DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205899PMC
November 2018
24 Reads
1 Citation
5.085 Impact Factor

Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate.

Hum Pathol 2018 09 6;79:151-159. Epub 2018 Jun 6.

Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 200127 Shanghai, China. Electronic address:

The correct diagnosis of small cell carcinoma (SCC) of the prostate is critical because of its aggressive behavior and poor prognosis. The histopathologic diagnosis could be challenging without neuroendocrine markers, which currently has limitations. Insulinoma-associated protein 1 (INSM1), a zinc-finger transcription factor, is considered to play an important role in the development of several neuroendocrine precursor cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2018.05.014DOI Listing
September 2018
14 Reads

Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.

Cold Spring Harb Perspect Med 2019 02 1;9(2). Epub 2019 Feb 1.

Englander Institute for Precision Medicine, Weill Cornell Medicine and New York-Presbyterian Hospital, New York, New York 10021.

Although a de novo clinical presentation of small cell neuroendocrine carcinoma of the prostate is rare, a subset of patients previously diagnosed with prostate adenocarcinoma may develop neuroendocrine features in later stages of castration-resistant prostate cancer (CRPC) progression as a result of treatment resistance. Despite sharing clinical, histologic, and some molecular features with other neuroendocrine carcinomas, including small cell lung cancer, castration-resistant neuroendocrine prostate cancer (CRPC-NE) is clonally derived from prostate adenocarcinoma. CRPC-NE therefore retains early prostate cancer genomic alterations and acquires new molecular changes making them resistant to traditional CRPC therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/cshperspect.a030593DOI Listing
February 2019
9 Reads

Transplantable Animal Studies and Whole-Body Optical Imaging in Prostate Carcinoma.

Methods Mol Biol 2018 ;1786:81-102

Department of Urology, Leiden University Medical Center, Leiden, The Netherlands.

Current treatments of advanced prostate cancer only marginally increase overall survival and can be regarded as predominantly palliative. Hence, there is an urgent need for novel therapeutic strategies for the treatment of primary tumors and, more importantly perhaps, for the prevention of tumor progression and metastasis formation. Clinically relevant preclinical models are therefore urgently needed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-7845-8_5DOI Listing
February 2019
10 Reads

[Development of Ectopic Adrenocorticotropic Hormone Syndrome in a Patient with Prostate Cancer during Combined Androgen Blockade Therapy].

Hinyokika Kiyo 2018 Apr;64(4):175-179

The Department of Urology, Hyogo Prefectural Nishinomiya Hospital.

A 74-year old man presented to us with difficulty urinating. The laboratory examinations revealed an elevated prostate-specific antigen (PSA) level. A prostate biopsy revealed prostate adenocarcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14989/ActaUrolJap_64_4_175DOI Listing
April 2018
9 Reads

Dual Paraneoplastic Endocrine Syndromes Heralding Onset of Extrapulmonary Small Cell Carcinoma: A Case Report and Narrative Review.

Front Endocrinol (Lausanne) 2018 18;9:170. Epub 2018 Apr 18.

Division of Endocrinology, Diabetes and Metabolism, Icahn School of Medicine at Mount Sinai, Mount Sinai St. Luke's and West Hospital Center, New York, NY, United States.

Objective: Extrapulmonary small cell carcinoma (EPSCC) is rare and frequent metastases at presentation can complicate efforts to identify a site of origin. In particular, SCC comprises <1% of prostate cancers and has been implicated in castration resistance.

Methods: Clinical, laboratory, imaging, and pathology data are presented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fendo.2018.00170DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932342PMC
April 2018
26 Reads

Anaplastic Lymphoma Kinase Mutation ( F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib.

Clin Cancer Res 2018 06 20;24(12):2732-2739. Epub 2018 Mar 20.

The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Small cell carcinoma of the prostate (SCCP) is an aggressive disease that can arise or by transdifferentiation from prostate adenocarcinoma. Alterations in anaplastic lymphoma kinase () gene are involved in neuroblastoma, lung cancer, and other malignancies, but its role in SCCP has not been documented. We describe a patient with refractory SCCP with F1174C-activating mutation who obtained clinical benefit from treatment with ALK inhibitor. Read More

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-0332DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715284PMC
June 2018
35 Reads
1 Citation
8.722 Impact Factor

Small Cell Carcinoma of Prostate: A Case Report of a Patient With Concomitant Transitional Cell Cancer of the Bladder.

J Investig Med High Impact Case Rep 2018 Jan-Dec;6:2324709618760644. Epub 2018 Mar 5.

Department of Hematology/Oncology, Joan C. Edwards School of Medicine, Marshall University, USA.

Small cell carcinomas (SCCs) are aggressive neoplasms commonly associated with a pulmonary origin. However, albeit rare, extrapulmonary SCC can occur in a variety of sites with an incidence in North America approximated to be 0.1% to 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2324709618760644DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844437PMC
March 2018
33 Reads

Variants of acinar adenocarcinoma of the prostate mimicking benign conditions.

Authors:
Peter A Humphrey

Mod Pathol 2018 01;31(S1):S64-70

Department of Pathology, Yale School of Medicine, New Haven, CT, USA.

Histological variants of acinar adenocarcinoma of the prostate may be of significance due to difficulty in diagnosis or due to differences in prognosis compared to usual acinar adenocarcinoma. The 2016 World Health Organization classification of acinar adenocarcinoma includes four variants that are deceptively benign in histological appearance, such that a misdiagnosis of a benign condition may be made. These four variants are atrophic pattern adenocarcinoma, pseudohyperplastic adenocarcinoma, microcystic adenocarcinoma, and foamy gland adenocarcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2017.137DOI Listing
January 2018
1 Read

[Four Cases of Bacteremia Caused by Helicobacter cinaedi in the Urological Ward at About the Same Time].

Hinyokika Kiyo 2017 Nov;63(11):461-463

The Department of Urology, Sapporo Medical University School of Medicine.

Here we report the outbreak of bacteremia caused by Helicobacter cinaedi (H. cinaedi) in the urology ward. Case 1 was a man in his seventies with prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14989/ActaUrolJap_63_11_461DOI Listing
November 2017
47 Reads

Coatomer subunit beta 2 (COPB2), identified by label-free quantitative proteomics, regulates cell proliferation and apoptosis in human prostate carcinoma cells.

Biochem Biophys Res Commun 2018 01 10;495(1):473-480. Epub 2017 Nov 10.

Department of Urology, Huashan Hospital, Fudan University, 12 Central Urumqi Rd, Shanghai 200040, PR China. Electronic address:

Label-free quantitative proteomics has broad applications in the identification of differentially expressed proteins. Here, we applied this method to identify differentially expressed proteins (such as coatomer subunit beta 2 [COPB2]) and evaluated the functions and molecular mechanisms of these proteins in prostate cancer (PCA) cell proliferation. Proteins extracted from surgically resected PCA tissues and adjacent tissues of 3 patients were analyzed by label-free quantitative proteomics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2017.11.040DOI Listing
January 2018
10 Reads

Clinical significance of SCCRO (DCUN1D1) in prostate cancer and its proliferation-inhibiting effect on Lncap cells.

Eur Rev Med Pharmacol Sci 2017 Oct;21(19):4283-4291

Department of Urology, Tianjin Union Medical Center, Hongqiao District, Tianjin, China.

Objective:   SCCRO/DCUN1D1/DCN1 (squamous cell carcinoma-related oncogene/defective in cullin neddylation 1 domain containing 1/defective in cullin neddylation) is considered as an oncogene, but its role in the prostate cancer (PC) is still not clear. The current study aims to investigate the expression of SCCRO in PC tumor tissues, further its clinical significance, and proliferation inhibiting effect on PC cells in vitro.

Patients And Methods: RT-PCR was used to detect the expression of SCCRO in PC tissue and corresponding adjacent normal tissues from 160 cases, and its relationship with clinical pathological characteristics was analyzed. Read More

View Article

Download full-text PDF

Source
October 2017
17 Reads

Intensity-modulated radiation therapy for small cell carcinoma of the prostate: A case report.

Rep Pract Oncol Radiother 2017 Sep-Oct;22(5):349-353. Epub 2017 Jul 22.

Department of Radiation Oncology, Tokyo Women's Medical University School of Medicine, 8-1, Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan.

Small cell carcinomas (SCC) make up only 1% of malignancies of the prostate. Reports of several case series have described outcomes of surgery and chemotherapy for SCC of the prostate, but few reports address radiotherapy. We treated a case of SCC of the prostate with intensity-modulated radiation therapy (IMRT) consisting of 70 Gy administered in 35 fractions followed by hormonal therapy using only luteinizing hormone-releasing hormone (LH-RH) agonist. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rpor.2017.06.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524305PMC
July 2017
16 Reads